Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.60
+0.23 (1.86%)
At close: May 22, 2026, 4:00 PM EDT
12.55
-0.05 (-0.40%)
Pre-market: May 26, 2026, 4:00 AM EDT

Intellia Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
66.0967.6757.8836.2852.1233.05
Revenue Growth (YoY)
45.04%16.92%59.55%-30.40%57.69%-43.01%
Gross Profit
66.0967.6757.8836.2852.1233.05
Selling, General & Admin
125.64119.8125.83116.590.3171.1
Research & Development
361.17388.86466.31435.07419.98229.81
Total Operating Expenses
486.81508.66592.14551.57510.29300.9
Operating Income
-420.72-440.99-534.26-515.29-458.16-267.85
Interest Income
25.829.247.8149.838.541.28
Other Non-Operating Income (Expense)
0.32-0.9-32.57-15.73-24.56-1.33
Total Non-Operating Income (Expense)
26.1228.315.2434.1-16.02-0.04
Pretax Income
-394.6-412.69-519.02-481.19-474.19-267.89
Net Income
-394.6-412.69-519.02-481.19-474.19-267.89
Net Income to Common
-394.6-412.69-519.02-481.19-474.19-267.89
Shares Outstanding (Basic)
11210899897771
Shares Outstanding (Diluted)
11210899897771
Shares Change (YoY)
11.16%9.64%11.35%15.33%8.57%26.63%
EPS (Basic)
-3.54-3.81-5.25-5.42-6.16-3.78
EPS (Diluted)
-3.54-3.81-5.25-5.42-6.16-3.78
Shares Outstanding
120.45116.32102.039387.174.49
Free Cash Flow
-363.63-395.87-354.66-408.07-346.85-237.79
Free Cash Flow Per Share
-3.24-3.65-3.59-4.60-4.51-3.35
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-636.56%-651.67%-923.10%-1420.51%-879.04%-810.37%
Profit Margin
-597.04%-609.85%-896.77%-1326.51%-909.78%-810.49%
FCF Margin
-550.18%-584.99%-612.78%-1124.94%-665.46%-719.41%
EBITDA
-411.24-431.22-523.98-506.32-450.59-260.96
EBITDA Margin
-622.23%-637.24%-905.33%-1395.77%-864.51%-789.52%
EBIT
-420.72-440.99-534.26-515.29-458.16-267.85
EBIT Margin
-636.56%-651.67%-923.10%-1420.51%-879.04%-810.37%
Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q